Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLY-200 in Obesity
NCT06259981Phase 2Completed
- Sponsor
- Glyscend Therapeutics
- Start
- May 2024
- Primary completion
- Oct 2024
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in obesity comparing GLY-200 with Placebo (2 arms). Primary endpoints: Percent change from baseline in weight at 16 weeks and Proportion of participants who achieve ≥ 5% body weight reduction at 16 weeks. Started May 2024; status: completed.
02
Drugs
GLY-200
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06259981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06259981.